Investigators sought to assess the effectiveness of SB5-adalimumab over 52 weeks in patients with Crohn disease after switching from originator-adalimumab.
Investigators assessed disparities in IBD clinical trials regarding a lack of inclusion of pregnant, lactating women; older adults; and racial and ethnic minorities.
Researchers compared the difference in overall health care utilization in patients with IBD who started anti-TNF therapy 2 years vs more than 2 years postdiagnosis.
Investigators analyzed adalimumab’s long-lasting clinical remission, associations of trough concentration, and linear growth in pediatric patients with Crohn disease.
Researchers assessed the association between simplified magnetic resonance index of activity and IC-measured inflammation levels in children with Crohn disease.
Investigators compared the safety and efficacy of higher induction regimens vs standard induction regimens for the treatment of moderately to severely active Crohn disease.
Investigators compared the safety and efficacy of endoscopic balloon dilation vs fully covered self-expandable metal stents for treatment of Crohn disease strictures.
The PAS is supported by data from the REFLECTIONS B538-12 study, which assessed multiple switches between Abrilada and Humira, in addition to methotrexate, in adults with moderate to severe rheumatoid arthritis.
Investigators assessed the relationship between physical activity, body mass index, and body composition among pediatric patients with inflammatory bowel disease.
Investigators highlight the burdens caused by unaddressed or uncontrolled symptoms of IBD and suggest ways physicians could address these burdens in clinical practice.
Investigators compared first-line infliximab therapy vs conventional treatment for achieving short- and long-term remission in pediatric patients with Crohn disease.
The incidence of Crohn disease is increasing in the US. Experts outline the risk factors, pathophysiology, and symptoms of Crohn disease as well as strategies for diagnosis and treatment of this disease in the primary care setting.
